

## **13-ICML SATELLITE SYMPOSIA PROGRAMS (updated to May 15, 2015)**

**Tuesday, June 16, from 12:00 to 14:00 (room B I)**

---

AMGEN (EUROPE) GmbH

### **NOVEL APPROACHES TO LYMPHOMA AND LEUKAEMIA: ENGAGING THE T CELL WITH BISPECIFIC ANTIBODY CONSTRUCTS**

Chair: M. Ghilmini, Bellinzona (Switzerland)

#### **WELCOME**

M. Ghilmini, Bellinzona (Switzerland)

#### **IMMUNOTHERAPY IN HAEMATOLOGICAL MALIGNANCIES**

M. Ghilmini, Bellinzona (Switzerland)

#### **HARNESSING THE IMMUNE SYSTEM WITH BITE ANTIBODIES CONSTRUCTS**

M. Klinger, Munich (Germany)

#### **EMERGING CLINICAL DATA WITH T-CELL-ENGAGING IMMUNOTHERAPIES**

**in NHL:** A. Viardot, Ulm (Germany)

**in ALL:** M. Topp, Wuerzburg (Germany)

#### **SUMMARY AND CLOSE**

M. Ghilmini, Bellinzona (Switzerland)

**Tuesday, June 16, from 15:30 to 17:30 (room B I)**

---

NOVARTIS ONCOLOGY

**MORE EVIDENCE, MORE OPTIONS: FIRST-LINE TREATMENT OF CLL**

Chair: K. Stamatopoulos, Thessaloniki (Greece)

**CHAIR'S WELCOME AND INTRODUCTION**

K. Stamatopoulos, Thessaloniki (Greece)

**FIRST-LINE THERAPY OF LESS FIT PATIENTS: OFATUMUMAB PLUS CHLORAMBUCIL**

M. Montillo, Milan (Italy)

**FIRST-LINE THERAPY OF LESS FIT PATIENTS: BENDAMUSTINE IN COMBINATION WITH ANTI-CD20 ANTIBODIES**

F. Offner, Gent (Belgium)

**NEW COMBINATIONS, INNOVATIVE SEQUENCING, TAILORED TREATMENTS. WHAT DOES THE FUTURE HOLD FOR CLL PATIENTS?**

S. Stilgenbauer, Ulm (Germany)

**PANEL DISCUSSION**

All speakers

**Tuesday, June 16, from 15:30 to 17:30 (room B II)**

---

CTI LIFE SCIENCES LIMITED AND SERVIER  
**CHANGING EXPECTATIONS IN THE TREATMENT OF RELAPSED AND  
REFRACTORY AGGRESSIVE NHL**

Chair: M. Ghielmini, Bellinzona (Switzerland)

**GUIDELINES AND CHALLENGES IN MANAGING RELAPSED AND REFRACTORY aNHL**

M. Ghielmini, Bellinzona (Switzerland)

**CLINICAL IMPLICATIONS OF THE NOVEL MECHANISM OF ACTION OF PIXANTRONE**

G. Minotti, Rome (Italy)

**TREATMENT OPTIONS FOR THE MANAGEMENT OF RELAPSED AND REFRACTORY DLBCL**

A. Davies, Southampton (UK)

**PRELIMINARY RESULTS WITH A NOVEL REGIMEN (PRE-BEN) IN LATE STAGE,  
REFRACTORY HIGH-GRADE NHL: THE NORDIC EXPERIENCE**

F. d'Amore, Aarhus (Denmark)

**Tuesday, June 16, from 19:00 to 21:00 (room A)**

---

BRISTOL-MYERS SQUIBB

**IMMUNO-ONCOLOGY: A NEW ERA IN HEMATOLOGY TREATMENT?  
EMERGING RESEARCH IN LYMPHOMA AND MYELOMA**

Chair: A. Engert, Cologne (Germany)

**WELCOME AND INTRODUCTION**

A. Engert, Cologne (Germany)

**WHY IMMUNO-ONCOLOGY IN HEMATOLOGY?**

A. Engert, Cologne (Germany)

**POTENTIAL ROLE OF I-O IN MYELOMA**

M. Mohty, Paris (France)

**A NEW ERA IN MYELOMA?**

K. Weisel, Tuebingen (Germany)

**POTENTIAL ROLE OF I-O IN LYMPHOMA**

S. Ansell, Rochester, MN (USA)

**A NEW ERA IN LYMPHOMA?**

P.L. Zinzani, Bologna (Italy)

**QUESTION AND ANSWER**

Full panel

**Tuesday, June 16, from 19:00 to 21:00 (room B I)**

---

**BAYER HEALTHCARE PHARMACEUTICALS, INC.  
THE EVOLVING THERAPEUTIC POTENTIAL OF PI3K INHIBITORS IN RELAPSED OR  
REFRACTORY NON-HODGKIN'S LYMPHOMA**

Chair: M. Ghielmini, Bellinzona (Switzerland)

**WELCOME, INTRODUCTION, AND CASE STUDY ON THE CURRENT STANDARD OF CARE  
IN RELAPSED OR REFRACTORY INDOLENT NHL**

M. Ghielmini, Bellinzona (Switzerland)

**MECHANISMS OF DRUG RESISTANCE IN MCL AND POTENTIAL MITIGATION STRATEGIES**

S. Chen-Kiang, New York, NY (USA)

**THE LANDSCAPE OF PI3K AND BCR SIGNALING INHIBITORS IN CLINICAL DEVELOPMENT  
FOR THE TREATMENT OF NHL**

J.P. Leonard, New York, NY (USA)

**CLINICAL ACTIVITY OF COPANLISIB IN NHL**

M. Dreyling, Munich (Germany)

**Q&A**

Panel

**CLOSING REMARKS**

M. Ghielmini, Bellinzona (Switzerland)

**Tuesday, June 16, from 19:00 to 21:00 (room B II)**

---

TAKEDA ONCOLOGY, SEATTLE GENETICS, INC, THE LEUKEMIA LYMPHOMA SOCIETY AND  
MEDICOM WORLDWIDE, INC

**CONTEMPORARY THERAPY FOR HODGKIN LYMPHOMA: WHERE ARE WE NOW?**

Chair: F. Cavalli, Bellinzona (Switzerland)

**WELCOME, INTRODUCTION, OVERVIEW**

F. Cavalli, Bellinzona (Switzerland)

**CURRENT AND EMERGING STRATEGIES IN FRONT LINE TREATMENT**

T. Illidge, Manchester (United Kingdom)

**RELAPSED REFRACTORY HODGKIN LYMPHOMA: CHANGING TREATMENT PARADIGMS?**

P. Borchmann, Cologne (Germany)

**WHERE DO WE GO FROM HERE: CONCLUSIONS AND WRAP UP**

F. Cavalli, Bellinzona (Switzerland)

**Wednesday, June 17, from 19:00 to 21:00 (room A)**

---

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON  
**CHALLENGING THE PARADIGMS IN B-CELL MALIGNANCIES**  
Chairs: M. Dreyling, Munich (Germany) and S. Rule, Plymouth (UK)

**WELCOME AND INTRODUCTION**

M. Dreyling, Munich (Germany)

**LEVERAGING THE B-CELL SIGNALLING PATHWAYS**

M. Dreyling, Munich (Germany)

**APPLYING BIOLOGICAL INSIGHTS TO THE CLINICAL MANAGEMENT OF MANTLE CELL LYMPHOMA**

M.L. Wang, Houston, TX (USA)

**PANEL DISCUSSION**

All

**INTEGRATING NOVEL THERAPIES INTO THE PRACTICAL MANAGEMENT OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA**

S. Treon, Boston, MA (USA)

**THE BIOLOGIC BASIS FOR IMPROVED CLINICAL MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA**

S. Stilgenbauer, Ulm (Germany)

**PANEL DISCUSSION**

All

**Wednesday, June 17, from 19:00 to 21:00 (room B)**

---

GILEAD SCIENCES EUROPE, LTD.

**NEW OPTIONS AND EVOLVING STRATEGIES IN THE MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES**

Co-Chairs: M. Hallek, Cologne (Germany) and G. Salles, Lyon (France)

**INTRODUCTION: A REVIEW OF THE CURRENT LANDSCAPE IN HEMATOLOGICAL MALIGNANCIES**

G. Salles, Lyon (France)

**NOVEL TARGETED THERAPIES IN DIFFICULT-TO-TREAT CLL**

M. Hallek, Cologne (Germany)

**CRITICAL CASES IN CLL – APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS**

B. Eichhorst, Cologne (Germany)

**TREATMENT STRATEGIES FOR PROLONGED CARE – OPTIONS AND SEQUENCING IN RELAPSED iNHL**

G. Salles, Lyon (France)

**CRITICAL CASES IN iNHL – APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS**

A. Davies, Southampton (UK)

**LOOKING FORWARD: THE EVOLVING TREATMENT PARADIGM IN CLL AND FL**

M. Dreyling, Munich (Germany)

**OPEN Q&A BASED ON DISCUSSIONS FROM THE PRESENTATIONS**

All, led by Co-Chairs

**SUMMARY AND CLOSE**

M. Hallek, Cologne (Germany)



**Thursday, June 18, from 19:00 to 21:00 (room A)**

---

CELGENE CORPORATION

**IMMUNE-BASED STRATEGIES TOWARDS ADVANCING THE TREATMENT OF B-CELL MALIGNANCIES**

Chair: F. Cavalli, Bellinzona (Switzerland)

**WELCOME AND INTRODUCTION**

F. Cavalli, Bellinzona (Switzerland)

**THE QUEST FOR ENDPOINTS IN GUIDING TREATMENT DECISIONS IN FOLLICULAR LYMPHOMA**

N. Fowler, Houston, TX (USA)

**NEW APPROACHES TO THE TREATMENT OF FOLLICULAR LYMPHOMA**

B.D. Cheson, Washington, DC (USA)

**OPTIMIZING TREATMENT OF RELAPSED AND/OR REFRACTORY MANTLE CELL LYMPHOMA**

M. Trněný, Prague (Czech Republic)

**IMPROVING ON FRONTLINE OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA**

U. Vitolo, Turin (Italy)

**ADVANCEMENT IN OUR UNDERSTANDING OF IMMUNOMODULATING AGENTS IN B-CELL MALIGNANCIES**

J.G. Gribben, London (UK)

**CLOSING REMARKS**

F. Cavalli, Bellinzona (Switzerland)

**Thursday, June 18, from 19:00 to 21:00 (room B)**

---

MUNDIPHARMA ONCOLOGY

**CLL AND FOLLICULAR NHL: CRITICAL REVIEW OF THE CURRENT GUIDELINES AND FUTURE PERSPECTIVES**

Co-chairs: J.G. Gribben, London (UK) and M. Ghielmini, Bellinzona (Switzerland)

**GERMAN PRACTICES IN CLL**

C. Wendtner, Munich (Germany)

**FRENCH PRACTICES IN CLL**

O. Tournilhac, Clermont Ferrand (France)

**UK PRACTICES IN FOLLICULAR NHL**

A. Davies, Southampton (UK)

**SWISS PRACTICES IN FOLLICULAR NHL**

M. Ghielmini, Bellinzona (Switzerland)

**Friday, June 19, from 18:45 to 19:45 (room A)**

---

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND - IOSI

*Supported by an unrestricted educational grant by GILEAD SCIENCES EUROPE, LTD.*

**THE BIG DEBATE: SHOULD WE ALWAYS AIM AT MINIMAL RESIDUAL DISEASE ERADICATION?**

Chair: M. Ghielmini, Bellinzona (Switzerland)

CLL – YES: J.G. Gribben, London (UK) vs  
– NO: S. Stilgenbauer, Ulm (Germany)

MCL – YES: M. Dreyling, Munich (Germany) vs  
– NO: J.P. Leonard, New York, NY (USA)

MM – YES: M. Cavo, Bologna (Italy) vs  
– NO: S.V. Rajkumar, Rochester, MN (USA)